Scarica l'app Stockscreener
18.84
1.62%
-0.31
Dopo l'orario di chiusura:
18.80
-0.04
-0.21%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Earnings Report: Should I hold or sell Viridian Therapeutics Inc nowForecast Cut & Daily Profit Focused Stock Screening - baoquankhu1.vn
Stifel Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $48 - moomoo.com
VRDN Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
EBIT per share of Viridian Therapeutics, Inc. – LSE:0K1R - TradingView
Viridian Therapeutics (VRDN) Is Down 32.5% After Debated Phase 3 Elegrobart DataWhat's Changed - Sahm
Viridian Therapeutics, Inc. (VRDN) Stock Price, News, Quote & History - Yahoo! Finance Canada
VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal? - Stocktwits
Viridian Therapeutics, Inc. (VRDN) stock price, news, quote and history - Yahoo Finance UK
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-04-02 - seekingalpha.com
Transcript : Viridian Therapeutics, Inc.Special Call - MarketScreener
Are Viridian Therapeutics' (VRDN) REVEAL-1 Results Enough To Redefine Its TED Competitive Position? - finance.yahoo.com
Viridian Therapeutics (VRDN) Target Price Lowered by Evercore IS - GuruFocus
What is HC Wainwright's Estimate for VRDN FY2027 Earnings? - MarketBeat
Discipline and Rules-Based Execution in VRDN Response - Stock Traders Daily
Viridian Therapeutics (VRDN) Soars 5.6%: Is Further Upside Left in the Stock? - qz.com
J.Jill, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire Inc.
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics (VRDN) Jumps 5.6%: Does the Stock Have More Room to Grow? - Bitget
Viridian's REVEAL-1: Clinically Active But Not Market-Dominating, Shares React Badly - seekingalpha.com
HC Wainwright Has Negative Outlook for VRDN Q1 Earnings - MarketBeat
Viridian Therapeutics, Inc. $VRDN Stock Position Decreased by JPMorgan Chase & Co. - MarketBeat
Aug Decliners: Will Viridian Therapeutics Inc benefit from geopolitical trends2026 Earnings Impact & Growth Focused Investment Plans - baoquankhu1.vn
Viridian releases phase 3 topline data on elegrobart for TED - Eyes On Eyecare
Goldman Sachs Adjusts Price Target for VRDN, Maintains Buy Ratin - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $36.00 at The Goldman Sachs Group - MarketBeat
Viridian Therapeutics (VRDN) Analyst Ratings Update: Wells Fargo Lowers Price Target | VRDN Stock News - GuruFocus
VRDN: Wedbush Lowers Price Target While Maintaining Outperform R - GuruFocus
Viridian Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - GlobeNewswire
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $20.00 at Wells Fargo & Company - MarketBeat
Viridian shares plummet on elegrobart trial results - The Pharma Letter
VRDN: Analyst Maintains 'Buy' Rating, Lowers Price Target to $22 - GuruFocus
HC Wainwright Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $22.00 - MarketBeat
H.C. Wainwright cuts Viridian Therapeutic price target on TED trial results - Investing.com Canada
Wolfe Research cuts Viridian Therapeutic price target on trial outlook - Investing.com
Wolfe Research cuts Viridian Therapeutic price target on trial outlook By Investing.com - Investing.com Canada
Viridian reports positive phase 3 trial results for TED drug By Investing.com - Investing.com Australia
Trade Recap: Can Viridian Therapeutics Inc be the next market leaderBuy Signal & Reliable Breakout Forecasts - baoquankhu1.vn
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease - BioSpace
Viridian Therapeutics price target lowered to $32 from $42 at Needham - TipRanks
Published on: 2026-03-31 08:41:04 - baoquankhu1.vn
Viridian Therapeutics price target lowered to $37 from $44 at Wedbush - TipRanks
Viridian Therapeutics (VRDN) Reports Success in Phase 3 Trial fo - GuruFocus
Viridian Therapeutics Plummets 32% on Mixed Trial Results Despite Record Trading Volume - Bitget
Viridian Therapeutics (VRDN) Shares Plummet Over 33% - GuruFocus
VRDN: Needham Lowers Price Target but Maintains Buy Rating | VRD - GuruFocus
Viridian Therapeutics (VRDN) Shares Plummet After Trial Results - GuruFocus
Viridian Therapeutics price target lowered to $29 from $45 at Jefferies - TipRanks
Viridian Therapeutics (VRDN) Experiences Significant Stock Decli - GuruFocus
Viridian Therapeutics (VRDN) Faces Mixed Data, Shares Fall - GuruFocus
Why This Amgen Rival Just Plummeted By A Third - Investor's Business Daily
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease (VRDN:NASDAQ) - seekingalpha.com
VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal? - MSN
Viridian dataset falls short of IV benchmark, says H.C. Wainwright - TipRanks
Viridian Therapeutics: Elegrobart Disappoints In REVEAL-1 Trial (NASDAQ:VRDN) - Seeking Alpha
Why is Viridian Therapeutics stock falling Monday? - MSN
Needham & Company LLC Lowers Viridian Therapeutics (NASDAQ:VRDN) Price Target to $32.00 - MarketBeat
Jefferies cuts Viridian Therapeutic stock price target on TED data By Investing.com - Investing.com Canada
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):